217 related articles for article (PubMed ID: 6533925)
1. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
[No Abstract] [Full Text] [Related]
2. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
[TBL] [Abstract][Full Text] [Related]
3. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
[No Abstract] [Full Text] [Related]
4. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
Graf H; Stummvoll HK; Meisinger V
Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of aluminum intoxication in chronic renal failure.
Simon P; Allain P; Ang KS; Cam G; Mauras Y
Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
[No Abstract] [Full Text] [Related]
6. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
[TBL] [Abstract][Full Text] [Related]
7. Improvement of anaemia with desferrioxamine in haemodialysis patients.
Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL
Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265
[TBL] [Abstract][Full Text] [Related]
8. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
Stummvoll HK; Graf H; Meisinger V
Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
[TBL] [Abstract][Full Text] [Related]
9. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
Simon P
Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
[No Abstract] [Full Text] [Related]
10. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR
Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321
[No Abstract] [Full Text] [Related]
11. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
Allain P; Chaleil D; Mauras Y; Beaudeau G; Varin MC; Poignet JL; Ciancioni C; Ang KS; Cam G; Simon P
Clin Chim Acta; 1987 Dec; 170(2-3):331-8. PubMed ID: 3436066
[TBL] [Abstract][Full Text] [Related]
13. Role of desferrioxamine in the treatment of dialysis encephalopathy.
Ackrill P; Ralston AJ; Day JP
Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
[No Abstract] [Full Text] [Related]
14. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
[No Abstract] [Full Text] [Related]
15. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
[TBL] [Abstract][Full Text] [Related]
16. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
[TBL] [Abstract][Full Text] [Related]
17. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
[TBL] [Abstract][Full Text] [Related]
18. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
[No Abstract] [Full Text] [Related]
19. Changes in bone histology after treatment with desferrioxamine.
Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
[No Abstract] [Full Text] [Related]
20. Aluminum kinetics in patients treated with hemodialysis or hemofiltration with sorbent recycling of ultrafiltrate.
Shapiro WB; Schilb TP; Porush JG
Trans Am Soc Artif Intern Organs; 1984; 30():342-6. PubMed ID: 6533906
[No Abstract] [Full Text] [Related]
[Next] [New Search]
